At Carlat we dig deeper: Last fall it was the possibility of suicidality with antidepressants when we see the real data; this winter, it was the lack of clinical relevance of CYP enzyme testing when we use medications carefully; and this spring, beneath the apparent weight of thousands of studies that turn out to be flawed, we found an absence of a definable effect size for the massive $17 billion applied behavioral analysis industry.

Topics: ABA | Applied Behavioral Analysis | Autism | Developmental Relationship Based Intervention | DRBI | Free Articles | Naturalistic Developmental-Behavioral Intervention | NDBI | treatment

How to respond to the seismic shift in our understanding of effect sizes in autism treatment? With better informed consent: we supplemented our interview with Dr Sandbank with an article by Dr Diane Cullinane on the three main kinds of autism treatment so that you will be prepared to help families know that they have choices.

Topics: ABA | Applied Behavioral Analysis | Autism | Developmental Relationship Based Intervention | DRBI | effect size | Naturalistic Developmental-Behavioral Intervention | NDBI

Thousands of studies that carry the weight of support for Applied Behavioral Analysis treatment for autism are flawed. See what we learned about effect sizes for this massive 17-billion-dollar industry and learn about why it is so hard to study more functional but meaningful change vs rote but less useful learning.

Clinicians need to efficiently respond to patient requests for records and document their considered judgment in decisions about restricting records to patients and families.

Topics: ADHD Attention Deficit Hyperactivity Disorder | ADHD-RS-5 | CGI | Clinical Global Impressions | Post-hoc Analysis ADHD Rating Scale-5 | Qelbree | Viloxazine | Weiss Functional Impairment Rating Scale-Parent (WFIRS-P)

As of April, 2021, we have a brand new non-stimulant medication approved for treatment of ADHD in the US. Are we excited? Does this represent an advance over other efforts to produce effective non-stimulant medications for ADHD, or is it another instance of ‘me too’? What does the supporting research tell us? And what side effects do we need to watch out for? Read and learn.

Topics: Aripiprazole | Autism | Bumetanide | complementary medicine | Lurasidone | Pharmacotherapy | Risperidone | Supplements

What’s new in psychopharmacological treatment for autism? We interviewed Dr. Matthew Krause on his recent review of seven studies covering the rationale for treatment, target symptoms, the use of antipsychotics, over the counter supplements, and some new ideas in pharmacotherapy for ASD.

Topics: children and adolescents | Electroconvulsive therapy | Research Update

Electroconvulsive therapy (ECT) remains both controversial and difficult to obtain for children and adolescents. Yet when our young patients have truly severe and life-threatening neuropsychiatric conditions, when medication is not going to cut it, we look to ECT for possible help. This research review offers guidance for use of ECT.

Topics: adolescents | children | GAMC | GDD | Gender Affirming Medical Care | Gender Dysphoric Disorder | Hormone Replacement Therapy | HRT | Mental Health | Suicidality

When is the best time to begin gender affirming medical care (GAMC) with respect to addressing the mental health status of children and adolescents with Gender Dysphoric Disorder? Should we begin Hormone Replacement Therapy early or wait until the adolescent is older? This research update will help you grapple with this very public debate.

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.